Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus NephritisBusiness Wire • 06/27/22
Down 10.7% in 4 Weeks, Here's Why Kezar Life Sciences, Inc. (KZR) Looks Ripe for a TurnaroundZacks Investment Research • 06/10/22
After Plunging 59.3% in 4 Weeks, Here's Why the Trend Might Reverse for Kezar Life Sciences, Inc. (KZR)Zacks Investment Research • 05/23/22
Kezar Life Sciences, Inc. (KZR) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 05/23/22
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/12/22
Wells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock PlungesBenzinga • 05/04/22
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and PolymyositisBusiness Wire • 05/03/22
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdateBusiness Wire • 03/17/22
Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care ConferenceBusiness Wire • 03/02/22
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus NephritisBusiness Wire • 11/15/21
Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.Business Wire • 11/10/21
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor MalignanciesBusiness Wire • 10/27/21